



July 24, 2012

PerkinElmer Receives State of Connecticut Clinical Laboratory Licensure and CLIA Certificate of Registration for Global DNA Sequencing Services

New CLIA certificate of registration will enable PerkinElmer's DNA Sequencing Services Laboratory to expand its offering into the clinical market

WALTHAM, Mass. - July 24, 2012 - [PerkinElmer, Inc.](#), a global leader focused on improving the health and safety of people and the environment, announced today that its DNA Sequencing Services Laboratory in Branford, Connecticut is now a Connecticut state licensed and CLIA registered clinical laboratory (CT license # CL0685).

PerkinElmer's DNA Sequencing Services Laboratory is designed to provide the highest quality, fastest response and most consistent sequencing in the industry, to complement a growing array of solutions for genomic researchers in medical, pharmaceutical, and academic settings. The CLIA certificate of registration will enable PerkinElmer's DNA Sequencing Services Laboratory to expand its offerings to include clinical sequencing services for specific disease analysis including cancer and Mendelian diseases, diagnostics services for new pharmaceuticals, and a better understanding of new drug clinical trials.

"Next Generation Sequencing has the potential to provide genomic information to better understand disease at the molecular level and to ultimately help improve patient care. The tests performed at the next generation sequencing laboratory include DNA exome and targeted sequencing as well as RNA sequencing. PerkinElmer's objective is to offer the broadest array of genomic and proteomic diagnostics as well as tools for more efficient research and drug discovery," said Richard Begley, president of Emerging Technologies at PerkinElmer. "The DNA Sequencing Services Laboratory will be operated with the same level of quality and excellence as our other CLIA diagnostics laboratories across PerkinElmer and we will begin accepting clinical samples immediately."

PerkinElmer provides a variety of technologies designed to address the needs of genomics researchers, including:

- [High-quality DNA/RNA extraction](#) using state-of-the art chemistries amenable to both high throughput and large volume applications.
- Best-in-class [plate readers](#) for high throughput assessment of DNA quantity and quality.
- Easy-to-use [statistical visualization and annotation tools](#) for microarray and NGS sequencing.
- [Library preparation](#) with automated liquid handling for better sample-to-sample uniformity and walk-away productivity.
- Secure, end-to-end [sequencing and analysis services](#) to accelerate your research goals and turn your valuable data into knowledge, in a CLIA environment.

For more information on PerkinElmer's next generation sequencing offerings, visit <http://www.perkinelmer.com/nextgensequencing>

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately \$1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

###

Media Contact:

Amanda Lazaro Connolly
Edelman (On behalf of PerkinElmer, Inc.)
Phone: 404-832-6785
Email: Amanda.Connolly@edelman.com